Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses.
Psychiatric symptoms in patients with multiple sclerosis.
Motor vehicle operation in the setting of multiple sclerosis with myelopathy: assessment, adaptive equipment, counseling, and cessation of driving.
Exploring brainstem function in multiple sclerosis by combining brainstem reflexes, evoked potentials, clinical and MRI investigations.
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
Biomarkers for multiple sclerosis.
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (DES)
Pharmacology of HIV integrase inhibitors.
Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.
Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins.
Stem cell therapy for white matter disorders: don't forget the microenvironment!
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis.
FTY720 is neuroprotective after cuprizone-induced central nervous system demyelination.
Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis.
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Biologic therapies: lessons from multiple sclerosis.
Transcriptomic meta-analysis of multiple sclerosis and its experimental models.
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Microparticle Platform
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases.
Psychological effects of calisthenic exercises on neuroinflammatory and rheumatic diseases.
Genetic and epigenetic fine mapping of causal autoimmune disease variants.
Protective effect of tanreqing injection on axon myelin damage in the brain of mouse model for experimental autoimmune encephalomyelitis.
Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate

Pages